Common Stock, par value $0.01 per share
- Symbol
- SRTS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Sensus Healthcare, Inc.
SRTSNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operation and Financial Condition On August 13, 2026, Sensus Healthcare, Inc. announced via press release its financial results for the second quarter of 2026. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The press release makes reference to certain non-GAAP financial measures.…
Press release in this filing
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights →Company context
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Current securities
Historical securities (1)
Registered securities in this filing
SENSUS HEALTHCARE, INC. · 8-K · Filed 2026-08-13
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operation and Financial Condition
On August 13, 2026, Sensus Healthcare, Inc. announced via press
release its financial results for the second quarter of 2026. A copy of the press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and incorporated herein by reference.
The press release makes reference to certain non-GAAP financial
measures. A reconciliation of the non-GAAP financial measures and other financial information is provided in the press release.
The information furnished under Item 2.02, including in Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific
reference in such filing.
Filed exhibits (1)
EX-99.1 2 g085863_ex99-1.htm EXHIBIT 99-1 Exhibit 99.1 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets Company Remains Focused on Delivering Strong Second Half Performance BOCA RATON, Fla., August 13, 2026 - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of units sold in the 2026 quarter, resulting in part from the inability to record the sale o…
Open exhibit ↗